Loading
A phase 2 trial of Sacituzumab tirumotecan, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07329322 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 30 participants planned, started 2026-03-30 and due to reach its primary completion in 2027-08-31. Interventions recorded: Sacituzumab Tirumotecan, Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, Small-cell lung cancer.
Shares Osimertinib, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sacituzumab tirumotecan, EGFR-mutated non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, EGFR-mutated non-small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.